Transplant rejection and paradigms lost

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2360-2362

  Strom, Terry B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; PERTUSSIS TOXIN; T LYMPHOCYTE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4;

ALLOGRAFT; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL TRANSFER; DENDRITIC CELL; GRAFT REJECTION; HISTOCOMPATIBILITY GENE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; HEART TRANSPLANTATION; KIDNEY TRANSPLANTATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84878559885     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69385     Document Type: Review

References (14)

1. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301-314.
2. Bolt S, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol. 1993;23(2):403-411.
3. Shulman Z, et al. Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin. Immunity. 2009; 30(3):384-396.
4. Famulski KS, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol. 2012;23(5):948-958.
5. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol. 2000;12(5):511-516.
6. Halloran PF, Fairchild RL. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant. 2008;8(8):1578-1579.
7. Oberbarnscheidt MH, et al. Memory T cells migrate to and reject vascularized cardiac allografts independent of the chemokine receptor CXCR3. Transplantation. 2011;91(8):827-832.
8. + T cell migration to vascularized transplants. J Clin Invest. 2013;123(6):2663-2671.
9. Calderon B, Carrero JA, Miller MJ, Unanue ER. Cellular and molecular events in the localization of diabetogenic T cells to islets of Langerhans. Proc Natl Acad Sci U S A. 2011;108(4):1561-1566.
10. Calderon B, Carrero JA, Miller MJ, Unanue ER. Entry of diabetogenic T cells into islets induces changes that lead to amplification of the cellular response. Proc Natl Acad Sci U S A. 2011;108(4):1567-1572.
11. Pober JS, Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol. 2012;33(1):49-57.
12. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007;7(8):622-632.
13. Keymeulen B, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598-2608.
14. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. 4th ed. Philadelphia, Pennsylvania, USA: Saunders; 2000.